Abstract
Clinical trials are underway infusing T cells genetically modified to be specific for B-cell malignancies using a chimeric antigen receptor (CAR) to redirect specificity for CD19. However, issues remain about whether the CAR can provide a fully competent application signal and whether other lymphocytes with lytic capacity can target CD19(+) tumors.
MeSH terms
-
Antigens, CD19 / immunology*
-
Antigens, CD19 / metabolism
-
B-Lymphocytes / immunology*
-
B-Lymphocytes / metabolism
-
Cytotoxicity, Immunologic
-
Humans
-
Killer Cells, Natural / immunology*
-
Killer Cells, Natural / metabolism
-
Precursor Cell Lymphoblastic Leukemia-Lymphoma / immunology
-
Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
-
Protein Engineering
-
Receptors, Antigen / genetics
-
Receptors, Antigen / immunology*
-
Recombinant Fusion Proteins / genetics
-
Recombinant Fusion Proteins / immunology*
-
T-Lymphocytes / immunology*
-
T-Lymphocytes / metabolism
Substances
-
Antigens, CD19
-
Receptors, Antigen
-
Recombinant Fusion Proteins